ArticleObesity pillars2025
Real-world effects of incretin-based Obesity medications on body composition.
Article in Obesity pillars, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Body Composition Remodelling During GLP-1-Based Therapy: A Systematic Review and Meta-Analysis Using a Hierarchical Physiological Framework.Diabetes, obesity & metabolism · 2026Pooled it
- Comparative Efficacy of Tirzepatide Versus Semaglutide for Weight Loss in Adults With Overweight or Obesity: A Systematic Review and Meta-Analysis of Head-to-Head Studies.Clinical obesity · 2026Pooled it
- Real-World vs. Randomized Trial Evidence for Incretin-Based Therapies: A Narrative Review.Journal of diabetes · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: This study evaluated the real-world impact of incretin-based obesity medications Semaglutide and Tirzepatide on body composition in people with obesity. The primary outcomes included changes in weight, waist circumference, skeletal muscle mass, fat mass, and visceral fat over 12 months. Methods: A retrospective observational study was conducted at Genesis Healthcare Centre, Dubai, UAE, from October 2022 to September 2024. A total of 269 adults (BMI ≥30 kg/m Results: Both medications significantly reduced weight, BMI, waist circumference, waist-to-height ratio, fat mass, and visceral fat (p < 0.001). At 6 months, weight loss was similar (-9.09 % vs -10.7 %), but by 12 months, Tirzepatide achieved greater reduction (22.02 % vs 11.59 %). Both improved glycemic control and liver function. Females exhibited greater weight loss. Lifestyle interventions supported skeletal muscle mass preservation. Conclusion: Semaglutide and Tirzepatide, significantly improved body composition, weight loss, and metabolic parameters in people with obesity. Tirzepatide demonstrated greater long-term efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.